Under the CVR Agreement, if all of the CVR milestones were not achieved at the specified timeline, the CVR Agreement would terminate automatically in accordance with its terms and the BMS CVRs would expire and be no longer eligible for payment.
Since the FDA’s approval of liso-cel did not occur by December 31, 2020, one of the three required CVR milestones was not met.  As a result, on January 1, 2021, the CVR Agreement terminated automatically in accordance with its terms and the BMS CVRs expired.  The BMS CVRs will no longer trade on the NYSE.
For additional information please call the Information Agent, EQ Shareowner Services at 1-833-503-4131.